Get the Stockscreener App
7.89
0.90%
0.09
Immatics N V stock is traded at $7.89, with a volume of 76,954.
It is up +0.90% in the last 24 hours and down -18.19% over the past month.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
See More
Previous Close:
$7.80
Open:
$7.8
24h Volume:
76,954
Relative Volume:
0.14
Market Cap:
$904.12M
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-6.6543
EPS:
-1.1857
Net Cash Flow:
$-13.78M
1W Performance:
-7.74%
1M Performance:
-18.19%
6M Performance:
-25.96%
1Y Performance:
-1.99%
1-Day Range:
$7.71
$8.04
1-Week Range:
$7.46
$8.67
52-Week Range:
$7.46
$13.77
Immatics N V Stock (IMTX) Company Profile
Compare IMTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| IMTX | 7.88 | 904.12M | 58.49M | -105.04M | -13.78M | -1.1857 |
| VRTX | 447.62 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.10 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.10 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.88 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.40 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Bank of America Has Lowered Expectations for Immatics (NASDAQ:IMTX) Stock Price - Defense World
Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Is Immatics N.V. (IMTX) the Best German Stock to Buy Now? - Insider Monkey
Immatics (NASDAQ:IMTX) Price Target Cut to $15.00 by Analysts at Bank of America - MarketBeat
Immatics: Q3 Earnings Snapshot - Milford Mirror
Immatics NV earnings beat by €0.14, revenue topped estimates - Investing.com UK
What Makes Immatics (IMTX) a New Buy Stock - Yahoo Finance
Immatics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immatics reports Q3 EPS (EUR 0.11) vs. (EUR 0.32) last year - TipRanks
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Immatics announces clinical data on TCER IMA402 targeting PRAME - TipRanks
Immatics sees cash runway into 2H27 - TipRanks
Immatics Announces Third Quarter 2024 Financial Results, - GlobeNewswire
T. Rowe Price Investment Management, Inc. Reduces Stake in Immatics NV - GuruFocus.com
Immatics (NASDAQ:IMTX) Reaches New 52-Week LowShould You Sell? - MarketBeat
When the Price of (IMTX) Talks, People Listen - Stock Traders Daily
Immatics N.V. Warrants (IMTXW) SEC Filing Summary - Quartzy
IMTX (Immatics NV) FCF Yield % : -4.41 (As of Nov. 11, 2024) - GuruFocus.com
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - 新浪香港
Immatics Unveils Promising TCR-T Therapy Developments - TipRanks
Immatics Announces Multiple Presentations at the 39th - GlobeNewswire
Wellington Management Group LLP Increases Stake in Immatics NV - GuruFocus.com
Piper Sandler Initiates Coverage of Immatics N.V. (IMTX) with Overweight Recommendation - MSN
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
232,900 Shares in Immatics (NASDAQ:IMTX) Bought by abrdn plc - MarketBeat
Objective long/short (IMTX) Report - Stock Traders Daily
Short Interest in Immatics (NASDAQ:IMTX) Expands By 5.3% - MarketBeat
Shareholders in Immatics (NASDAQ:IMTX) have lost 35%, as stock drops 6.3% this past week - Simply Wall St
Immatics N.V. (NASDAQ:IMTX) is a favorite amongst institutional investors who own 50% - Yahoo Finance
Perceptive Advisors LLC Reduces Stake in Immatics NV - Yahoo Finance
Immatics N.V. Announces Major Share Offering - TipRanks
Market Update: Immatics N.V (IMTX) Sees Negative Movement, Closing at 9.30 - The Dwinnex
Immatics (NASDAQ:IMTX) Short Interest Update - MarketBeat
It makes sense and dollars to buy Immatics N.V (IMTX) stock - SETE News
206,920 Shares in Immatics (NASDAQ:IMTX) Bought by Cubist Systematic Strategies LLC - MarketBeat
Immatics: A Promising TCR Pipeline (NASDAQ:IMTX) - Seeking Alpha
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception - BioCentury
Immatics (NASDAQ:IMTX) Sees Large Volume IncreaseWhat's Next? - MarketBeat
A closer look at IMTX’s price-to-free cash flow ratio - US Post News
Ratio Analysis: Unpacking Immatics N.V (IMTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Immatics Advances IMA203 to Phase 3 Trial in Melanoma - Yahoo Finance
Immatics Announces Pricing of $150 Million Public Offering - StockTitan
Immatics Off To Phase III With IMA203 After Positive Melanoma Results - Scrip
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? - AOL
IMTX: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Immatics Announces Proposed $150 Million Public Offering - GlobeNewswire
Immatics (NASDAQ:IMTX) Shares Gap DownHere's What Happened - MarketBeat
Form 424B2 Immatics N.V. - StreetInsider.com
Immatics provides update on Phase 1b trial of ACTengine in melanoma - TipRanks
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):